Skip to main content
. 2020 Aug;32(4):516–529. doi: 10.21147/j.issn.1000-9604.2020.04.09

4. Economic impact of overall expenditure on liver cancer patient’s family.

Variables Expenditure of newly diagnosed course/Annual expenditure of illness* (CNY) (N=2,175) Self-reported predicted reimbursement ratio (%) (N=2,175) Out-of-pocket expenditure**(A) (CNY) (N=2,175) Previous year household income (N=2,153 ) Self-reported degree of economic
pressure (%) (N=2,210)
Amount (B) (CNY) Ratio (A/B) Not at all Somewhat but manageable Heavy Overwhelmed P***
*, The 12-month duration covers 2 months before and 10 months after the diagnosis; **, Out-of-pocket expenditure=(∑(1 − Self-reported predicted reimbursement ratio) × Medical expenditure of newly diagnosed course + Non-medical expenditure of newly diagnosed course)/n; ***, Chi-square tests; CNY, Chinese Yuan.
Total 46,070 46.9 24,953 56,468 0.4 7.8 15.0 31.4 45.8
Hospital type
 General 38,207 57.5 18,562 73,501 0.3 12.8 20.0 32.9 34.4 <0.001
 Specialized 48,611 43.3 27,074 50,961 0.5 6.2 13.4 31.0 49.5
Age at diagnosis (year)
 <45 51,019 43.2 29,796 62,202 0.5 6.4 11.7 31.1 50.8 <0.001
 45−54 46,775 44.3 26,440 56,066 0.5 5.3 15.4 29.5 49.8
 55−64 45,170 48.5 24,050 54,510 0.4 8.0 14.3 32.8 44.9
 ≥65 42,824 50.5 20,660 55,676 0.4 11.9 17.9 32.2 38.0
Gender
 Male 46,569 46.7 25,183 56,622 0.4 7.9 14.6 31.5 45.9 0.800
 Female 44,171 47.4 24,065 55,873 0.4 7.2 16.3 31.3 45.2
Education
 Primary school or below 40,974 41.4 23,906 43,198 0.6 6.3 11.0 32.7 50.0 <0.001
 Junior high school 42,973 44.2 24,388 54,542 0.4 5.2 16.2 32.5 46.1
 Senior high school 49,755 52.0 25,614 63,641 0.4 10.9 15.5 29.1 44.5
 Undergraduate or over 64,114 61.2 28,879 85,523 0.3 14.1 21.4 29.6 35.0
Occupation
 Farmer 41,180 36.1 26,514 41,770 0.6 2.0 8.4 33.4 56.2 <0.001
 Enterprise or company
 employee/worker
45,802 56.1 21,044 62,700 0.3 13.6 20.0 27.7 38.7
 Self-employed or
 unemployed
46,555 41.6 27,577 72,497 0.4 8.0 15.1 30.9 46.0
 Retiree 54,054 60.7 25,236 67,599 0.4 15.0 20.1 29.5 35.5
 Staff in institution/civil
 servant
60,834 64.6 24,240 68,698 0.4 9.2 26.6 31.8 32.4
 Other 45,245 42.7 26,482 56,242 0.5 3.0 9.1 60.6 27.3
Health-care insurance type
 Urban employees basic
 medical insurance
49,419 58.6 22,234 64,584 0.3 14.6 18.5 27.3 39.6 <0.001
 Urban residents basic
 medical insurance
47,668 49.8 23,591 60,320 0.4 6.0 18.8 33.8 41.4
 New rural cooperative
 medical scheme
42,510 36.8 27,571 44,620 0.6 1.9 9.6 33.6 54.8
 Commercial insurance 22,221 10.6 20,336 46,842 0.4 5.3 5.3 36.8 52.6
 Self-financed 41,799 0.0 41,799 104,514 0.4 7.5 22.5 40.0 30.0
 Other 59,682 69.9 20,257 72,136 0.3 13.6 18.2 40.9 27.3
Previous year household income (CNY)
 <20,000 39,281 38.0 24,624 10,888 2.3 0.4 4.9 20.6 74.1 <0.001
 20,000−39,999 44,199 42.0 26,124 26,983 1.0 2.7 8.1 31.6 57.6
 40,000−69,999 45,246 46.9 24,011 50,150 0.5 8.1 16.6 31.0 44.2
 ≥70,000 51,529 55.5 25,012 108,404 0.2 15.0 24.3 35.3 25.4
Clinical stage
 I 45,032 48.0 23,118 57,594 0.4 5.7 15.8 28.3 50.2 0.004
 II 44,479 47.9 24,062 53,461 0.5 6.5 15.5 26.0 51.9
 III 44,573 44.6 24,592 54,950 0.5 9.0 13.7 34.9 42.5
 IV 45,446 48.1 25,102 61,929 0.4 7.2 17.3 29.9 45.6
Therapeutic regimen
 Surgery 59,301 47.0 32,520 61,581 0.5 8.5 14.2 36.9 40.4 0.005
 Chemotherapy 42,480 50.3 21,726 59,854 0.4 9.4 15.9 25.3 49.4
 Surgery and postoperative
 chemotherapy
52,035 48.5 27,420 60,440 0.5 2.4 17.3 40.2 40.2
 Symptomatic treatment 41,113 44.5 22,958 53,408 0.4 8.26 14.65 30.68 46.4
 Concurrent
 chemoradiotherapy
52,664 39.1 35,458 59,800 0.6 15.8 26.3 36.8 21.1
 Radiotherapy 49,076 52.7 24,359 54,040 0.5 6.3 21.9 25.0 46.9
 Neoadjuvant
 chemoradiotherapy
 and surgery
44,756 56.5 23,002 61,135 0.4 0.00 18.2 45.5 36.4
Pathological type
 Hepatocellular carcinoma 48,150 48.1 25,896 56,536 0.5 5.2 15.2 30.5 49.1 <0.001
 Other 47,567 50.2 23,787 69,449 0.3 21.5 22.3 36.5 19.7